You just read:

In the Race for Alternative MOA Biologic in Crohn's Disease, Takeda's Entyvio Maintains the Lead, but Janssen's Stelara is Gaining Fast

News provided by

Spherix Global Insights

Jun 27, 2017, 04:00 ET